Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Memphasys Ltd ( (AU:MEM) ) is now available.
Memphasys Limited announced the completion of the Last Patient Last Visit (LPLV) for its pivotal clinical trial of the Felix™ System, a cutting-edge sperm selection technology for Assisted Reproductive Technology (ART) procedures. With the data lock expected within two weeks and preliminary results slated for early March 2025, the trial data will be a critical component of the company’s CE Mark submission, paving the way for market entry in Europe, followed by Australia and India. The data will also facilitate discussions with distribution partners, potentially boosting sales and accelerating global market expansion.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is a biotechnology company specializing in advanced reproductive technology. The company develops medical devices, diagnostics, and proprietary media for both human and animal applications, with flagship technologies including the Felix™ and RoXsta™ Systems aimed at enhancing fertility outcomes globally.
Average Trading Volume: 10,181,599
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$12.4M
See more insights into MEM stock on TipRanks’ Stock Analysis page.
